Vysis Expands Scientific Advisory Board

Noted Oncologists and Research Scientists

Bring Strong National and International Capability



Apr 23, 2001, 01:00 ET from Vysis, Inc.

    DOWNERS GROVE, Ill., April 23 /PRNewswire/ -- Vysis, Inc. (Nasdaq:   VYSI),
 a developer and marketer of DNA-based clinical products providing information
 for genomic disease management, announced today that it has expanded its
 Scientific Advisory Board (SAB) to 13 members. The five newly appointed
 advisors bring impressive credentials and extensive knowledge and experience
 in genomics, cancer research and pathology -- fields that support the
 strategic focus of the company.  The addition of these experts further
 strengthens Vysis' international representation. The latest members to the SAB
 include:
 
      *  Carlos Cordone-Cardo, M.D., Ph.D., Director, Division of Molecular
         Pathology, Memorial Sloane-Kettering Cancer Center;
      *  Ferdinand Hofstaedter, M.D., University of Regensburg, Head of
         Department of Pathology;
      *  Edison T. Liu, M.D., Executive Director Singapore Genomic Programme
         Singapore;
      *  Michael F. Press, M.D., Ph.D., The Harold E. Lee Chair in Cancer
         Research Professor, The University of Southern California;
      *  Guido Sauter, M.D., Professor of Pathology, Institute of Pathology,
         University of Basel.
 
     "Our scientific advisory board is made up of some of the most highly
 regarded scientist in their various disciplines.  We are fortunate to be able
 to work with such an accomplished group on a routine basis. They are
 instrumental in helping to guide the scientific and medical direction of the
 company, and are a key component to our ongoing success," said John Bishop,
 Vysis president and chief executive officer.
     The new additions complement Vysis existing group of highly regarded SAB
 members, which includes:
     Robert B. Jenkins, M.D., Ph.D., Professor, Laboratory Medicine, Mayo
 Medical School, Mayo Clinic; David H. Ledbetter, Ph.D., Marjorie I. and
 Bernard A. Mitchell Professor and Chair, Department of Human Genetics, The
 University of Chicago; Kenneth L. Melmon, M.D., Arthur L. Bloomfeld Professor
 of Medicine and Molecular Pharmacology, Emeritus, Chief Medical Officer,
 SKOLAR, M.D.; David H. Persing, M.D., Ph.D., Vice President, Diagnostic
 Development, Corixa Corporation; Daniel Pinkel, Ph.D., Professor, Department
 of Laboratory Medicine, Comprehensive Cancer Center, University of California,
 San Francisco; Hans J. Tanke, Ph.D., Professor of Molecular Cell Biology,
 Leiden University Medical Center; Stephen T. Warren, Ph.D., William Patterson
 Timmie Professor of Human Genetics and Chairman, Department of Genetics
 Investigator, Howard Hughes Medical Institute, Emory University School of
 Medicine.
 
     Vysis, Inc. of Downers Grove, IL, is a genomic disease management company
 that develops, commercializes and markets DNA-based clinical products
 providing information critical to the evaluation and management of cancer,
 prenatal disorders and other genetic diseases. The company has direct sales
 operations in the United States and Europe, a marketing partnership in Japan
 with Fujisawa Pharmaceutical Co., and a worldwide distribution network.
     The statements in this press release concerning Vysis' future financial
 results as well as any other statements which are not historical facts, are
 forward-looking statements and are subject to risks and uncertainties inherent
 in the company's business.  These risks and uncertainties, which could cause
 actual results to differ materially from those expressed or implied by the
 forward-looking statements, include:  the market acceptance of the company's
 clinical products; the extent to which the clinicians or laboratories
 performing the procedures with the company's products are able to obtain
 third-party reimbursement; the ability of the company to successfully market
 and sell its clinical products, other products and equipment; competition;
 compliance by the company with regulatory requirements and the timely receipt
 of necessary governmental approvals; the company's ability to manufacture
 products in sufficient quantities; the company's ability to maintain
 intellectual property protection for its proprietary products, to defend its
 existing intellectual property rights from challenges by third parties, and to
 avoid infringing intellectual property rights of third parties; and the
 company's cost control efforts.   In addition, a detailed discussion of risks
 and uncertainties may be found in the company's periodic filings with the
 Securities and Exchange Commission.  Vysis disclaims any intent or obligation
 to update these forward-looking statements.
 
     More information about the PathVysion HER-2 technology and associated
 products can be obtained on the Vysis web site at www.vysis.com or by
 contacting Vysis.
 
     To receive Vysis, Inc.'s latest news release and other corporate
 documents, free of charge via fax, simply dial 1-800-PRO-INFO.  Use company
 ticker VYSI.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X37438888
 
 

SOURCE Vysis, Inc.
    DOWNERS GROVE, Ill., April 23 /PRNewswire/ -- Vysis, Inc. (Nasdaq:   VYSI),
 a developer and marketer of DNA-based clinical products providing information
 for genomic disease management, announced today that it has expanded its
 Scientific Advisory Board (SAB) to 13 members. The five newly appointed
 advisors bring impressive credentials and extensive knowledge and experience
 in genomics, cancer research and pathology -- fields that support the
 strategic focus of the company.  The addition of these experts further
 strengthens Vysis' international representation. The latest members to the SAB
 include:
 
      *  Carlos Cordone-Cardo, M.D., Ph.D., Director, Division of Molecular
         Pathology, Memorial Sloane-Kettering Cancer Center;
      *  Ferdinand Hofstaedter, M.D., University of Regensburg, Head of
         Department of Pathology;
      *  Edison T. Liu, M.D., Executive Director Singapore Genomic Programme
         Singapore;
      *  Michael F. Press, M.D., Ph.D., The Harold E. Lee Chair in Cancer
         Research Professor, The University of Southern California;
      *  Guido Sauter, M.D., Professor of Pathology, Institute of Pathology,
         University of Basel.
 
     "Our scientific advisory board is made up of some of the most highly
 regarded scientist in their various disciplines.  We are fortunate to be able
 to work with such an accomplished group on a routine basis. They are
 instrumental in helping to guide the scientific and medical direction of the
 company, and are a key component to our ongoing success," said John Bishop,
 Vysis president and chief executive officer.
     The new additions complement Vysis existing group of highly regarded SAB
 members, which includes:
     Robert B. Jenkins, M.D., Ph.D., Professor, Laboratory Medicine, Mayo
 Medical School, Mayo Clinic; David H. Ledbetter, Ph.D., Marjorie I. and
 Bernard A. Mitchell Professor and Chair, Department of Human Genetics, The
 University of Chicago; Kenneth L. Melmon, M.D., Arthur L. Bloomfeld Professor
 of Medicine and Molecular Pharmacology, Emeritus, Chief Medical Officer,
 SKOLAR, M.D.; David H. Persing, M.D., Ph.D., Vice President, Diagnostic
 Development, Corixa Corporation; Daniel Pinkel, Ph.D., Professor, Department
 of Laboratory Medicine, Comprehensive Cancer Center, University of California,
 San Francisco; Hans J. Tanke, Ph.D., Professor of Molecular Cell Biology,
 Leiden University Medical Center; Stephen T. Warren, Ph.D., William Patterson
 Timmie Professor of Human Genetics and Chairman, Department of Genetics
 Investigator, Howard Hughes Medical Institute, Emory University School of
 Medicine.
 
     Vysis, Inc. of Downers Grove, IL, is a genomic disease management company
 that develops, commercializes and markets DNA-based clinical products
 providing information critical to the evaluation and management of cancer,
 prenatal disorders and other genetic diseases. The company has direct sales
 operations in the United States and Europe, a marketing partnership in Japan
 with Fujisawa Pharmaceutical Co., and a worldwide distribution network.
     The statements in this press release concerning Vysis' future financial
 results as well as any other statements which are not historical facts, are
 forward-looking statements and are subject to risks and uncertainties inherent
 in the company's business.  These risks and uncertainties, which could cause
 actual results to differ materially from those expressed or implied by the
 forward-looking statements, include:  the market acceptance of the company's
 clinical products; the extent to which the clinicians or laboratories
 performing the procedures with the company's products are able to obtain
 third-party reimbursement; the ability of the company to successfully market
 and sell its clinical products, other products and equipment; competition;
 compliance by the company with regulatory requirements and the timely receipt
 of necessary governmental approvals; the company's ability to manufacture
 products in sufficient quantities; the company's ability to maintain
 intellectual property protection for its proprietary products, to defend its
 existing intellectual property rights from challenges by third parties, and to
 avoid infringing intellectual property rights of third parties; and the
 company's cost control efforts.   In addition, a detailed discussion of risks
 and uncertainties may be found in the company's periodic filings with the
 Securities and Exchange Commission.  Vysis disclaims any intent or obligation
 to update these forward-looking statements.
 
     More information about the PathVysion HER-2 technology and associated
 products can be obtained on the Vysis web site at www.vysis.com or by
 contacting Vysis.
 
     To receive Vysis, Inc.'s latest news release and other corporate
 documents, free of charge via fax, simply dial 1-800-PRO-INFO.  Use company
 ticker VYSI.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X37438888
 
 SOURCE  Vysis, Inc.